Tenofovir Disoproxil Fumarate: A Review of its Use in the Management of HIV infection

Authors: Lyseng-Williamson Katherine A.; Reynolds Neil A.; Plosker Greg L.

Source: Drugs, Volume 65, Number 3, 2005 , pp. 413-432(20)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

Tenofovir disoproxil fumarate (tenofovir DF; Viread^®), an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral regimen, oral tenofovir DF 300mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication.

Keywords: Adis Drug Evaluations; Tenofovir disoproxil fumarate, therapeutic use; HIV infections, treatment

Document Type: Research article

Affiliations: 1: Adis International Limited, Auckland, New Zealand

Publication date: 2005-01-01